0001104659-23-005053.txt : 20230119
0001104659-23-005053.hdr.sgml : 20230119
20230119165723
ACCESSION NUMBER: 0001104659-23-005053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230117
FILED AS OF DATE: 20230119
DATE AS OF CHANGE: 20230119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hesslein Robert W.
CENTRAL INDEX KEY: 0001585018
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 23538001
MAIL ADDRESS:
STREET 1: C/O FOUNDATION MEDICINE, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B3501
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
tm233882-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-01-17
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001585018
Hesslein Robert W.
C/O VOYAGER THERAPEUTICS, INC.,
64 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Senior VP & General Counsel
Common Stock
2023-01-17
4
S
0
1396
9.57
D
113567
D
Common Stock
2023-01-17
4
S
0
792
10.34
D
112775
D
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.19 to $10.18, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
/s/ Robert W. Hesslein
2023-01-19